{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:08:09Z","timestamp":1793257689962,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018866","name":"Paula and Rodger Riney Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jtct.2024.12.023","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T12:13:28Z","timestamp":1735647208000},"page":"166.e1-166.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"31","author":[{"given":"Oren","family":"Pasvolsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Marcoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Den\u00e1i R.","family":"Milton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babar","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-6453","authenticated-orcid":false,"given":"Qaiser","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Srour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0524-267X","authenticated-orcid":false,"given":"Paul","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Ramdial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6034-8939","authenticated-orcid":false,"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naureen","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosra","family":"Aljawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody R.","family":"Becnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheeba K.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-5037","authenticated-orcid":false,"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar H.","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jtct.2024.12.023_bib0001","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jtct.2024.12.023_bib0002","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.jtct.2024.12.023_bib0003","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2024.12.023_bib0004","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2352-3026(22)00360-X","article-title":"Upfront autologous transplantation still improving outcomes in patients with multiple myeloma","volume":"10","author":"Beksac","year":"2023","journal-title":"Lancet Haematol"},{"issue":"23","key":"10.1016\/j.jtct.2024.12.023_bib0005","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2024.12.023_bib0006","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.jtct.2024.12.023_bib0007","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023023597","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma","volume":"143","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.jtct.2024.12.023_bib0008","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2024.12.023_bib0009","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2023-188844","article-title":"RADAR trial: MRD response adapted trial for newly diagnosed transplant eligible myeloma patients","volume":"142","author":"Ramasamy","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2024.12.023_bib0010","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bjh.15800","article-title":"Substratification of patients with newly diagnosed standard-risk multiple myeloma","volume":"185","author":"Binder","year":"2019","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.jtct.2024.12.023_bib0011","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.clml.2015.07.641","article-title":"Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation","volume":"15","author":"Kazmi","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.jtct.2024.12.023_bib0012","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/ejh.12826","article-title":"Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma","volume":"98","author":"Badar","year":"2017","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2024.12.023_bib0013","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jtct.2024.12.023_bib0014","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2024.12.023_bib0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-020-00348-5","article-title":"Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response","volume":"10","author":"Abdallah","year":"2020","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.jtct.2024.12.023_bib0016","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.bbmt.2016.07.007","article-title":"Post-transplant outcomes in high-risk compared with non-high-risk multiple myeloma: a CIBMTR analysis","volume":"22","author":"Scott","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2024.12.023_bib0017","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-023-00973-w","article-title":"Outcomes of patients with multiple myeloma and 1q gain\/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience","volume":"14","author":"Pasvolsky","year":"2024","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.jtct.2024.12.023_bib0018","doi-asserted-by":"crossref","first-page":"260.e1","DOI":"10.1016\/j.jtct.2023.01.010","article-title":"Autologous stem cell transplantation for patients with multiple myeloma with translocation (4;14): the MD Anderson cancer center experience","volume":"29","author":"Pasvolsky","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.023_bib0019","first-page":"1","article-title":"Real-world outcomes of upfront autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma with deletion 17p","volume":"0","author":"Marcoux","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2024.12.023_bib0020","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-024-01062-2","article-title":"Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation","volume":"14","author":"Pasvolsky","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.jtct.2024.12.023_bib0021","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41408-023-00905-8","article-title":"Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database","volume":"13","author":"C\u00f4t\u00e9","year":"2023","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.jtct.2024.12.023_bib0022","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamaoncol.2018.2961","article-title":"Maintenance treatment and survival in patients with myeloma: a systematic review and network meta-analysis","volume":"4","author":"Gay","year":"2018","journal-title":"JAMA Oncol"},{"issue":"29","key":"10.1016\/j.jtct.2024.12.023_bib0023","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2024.12.023_bib0024","doi-asserted-by":"crossref","first-page":"752.e1","DOI":"10.1016\/j.jtct.2022.07.028","article-title":"Lenalidomide-based maintenance after autologous hematopoietic stem cell transplantation for patients with high-risk multiple myeloma","volume":"28","author":"Pasvolsky","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2024.12.023_bib0025","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2024.12.023_bib0026","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-023-00882-y","article-title":"Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma","volume":"13","author":"Tan","year":"2023","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.jtct.2024.12.023_bib0027","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41409-022-01697-4","article-title":"KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma","volume":"57","author":"Gaballa","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.jtct.2024.12.023_bib0028","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jtct.2024.12.023_bib0029","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2021011101","article-title":"Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA","volume":"139","author":"Cavo","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2024.12.023_bib0030","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/cncr.35171","article-title":"Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation","volume":"130","author":"Pasvolsky","year":"2024","journal-title":"Cancer"},{"issue":"16_suppl","key":"10.1016\/j.jtct.2024.12.023_bib0031","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2024.42.16_suppl.106","article-title":"Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)","volume":"42","author":"Derman","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.jtct.2024.12.023_bib0032","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.jtct.2024.12.023_bib0033","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamaoncol.2022.2424","article-title":"Elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma without transplant intent: a phase 2 measurable residual disease-adapted study","volume":"8","author":"Derman","year":"2022","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2024.12.023_bib0034","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2024.12.023_bib0035","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_433520","article-title":"Navigating high-risk and ultrahigh-risk multiple myeloma: challenges and emerging strategies","volume":"44","author":"Rees","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"17","key":"10.1016\/j.jtct.2024.12.023_bib0036","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2024.12.023_bib0037","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724008418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724008418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:38:34Z","timestamp":1772325514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724008418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2666636724008418"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.12.023","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}